课题基金 / 基金详情

Novel generic vaccine approaches applied for the prevention of hepatitis C and influenza virus infections.

Novel generic vaccine approaches applied for the prevention of hepatitis C and influenza virus infections.
用于预防丙型肝炎和流感病毒感染的新型仿制疫苗方法。
批准号:
nhmrc : 436729
负责人:
Prof Hans Netter
金额:
$26.16万
依托单位:
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2007
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2007-01-01 至 2009-12-31

项目摘要

项目成果

Prof Hans Netter的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
For the induction of good immune responses, antigens should be delivered in several copies on a defined particle. The small envelope protein (HBsAg) encoded by the hepatitis B virus (HBV) has the capacity to self-assemble with host derived lipids into VLPs. HBsAg VLPs are the sole component of one of the most successful vaccines, and clinical trials have shown that they are a successful delivery system for foreign epitopes or protein domains. Hepatitis C virus (HCV) and Influenza viruses are major human pathogens. HCV has infected 200 million people worldwide, and there is no effective vaccine available. Influenza continues to affect thousands of people each year causing epidemics with severe morbidity and considerable mortality. Current influenza vaccines are mostly inactivated formulations and they exhibit poor immunogenicity in immunological naive persons such as children and in the elderly. The influenza vaccines are not optimal for stimulation of cell-mediated immunity. We propose to use particulate antigens as a delivery platform for influenza and HCV-specific epitopes with the focus to develop approaches to target various HCV and influenza strains, including H5N1 bird influenza. We have successfully produced modified VLPs containing HCV-specific sequences, which are able to induce anti-HCV antibodies with neutralising capacity. We hypothesise that the design of VLPs with an appropriate set of HCV-specific antigens will enhance the neutralising capacity of anti-HCV sera and this may overcome strain specificity. This application will exploit a prototype delivery system to induce antibody and also cellular responses against a variety of HCV- and influenza specific target sequences (epitopes). The outcome of this study will be a prototype multivalent vaccine to a range of HCV- and influenza-specific epitopes. As a delivery system this will be ideal for vaccination against agents that are highly variable.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Comparative expression studies to identify cellular factors promoting Hendra virus replication for a comprehensive understanding of Hendra virus pathogenesis
  • 批准号:
    nhmrc : 1044228
  • 项目类别:
    Targeted Calls
  • 资助金额:
    $24.98万
  • 财政年份:
    2012
  • 负责人:
    Prof Hans Netter
  • 依托单位:
国内基金
海外基金
Hecke-Clifford 代数及其表示
  • 批准号:
    11101031
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    22.0万元
  • 批准年份:
    2011
  • 负责人:
    万金奎
  • 依托单位:
关于权投射线上凝聚层范畴的研究
  • 批准号:
    10926041
  • 项目类别:
    数学天元基金项目
  • 资助金额:
    3.0万元
  • 批准年份:
    2009
  • 负责人:
    陈健敏
  • 依托单位:
约化群GL(n, F)的表示--F是非阿基米德局部域
  • 批准号:
    10701034
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    18.0万元
  • 批准年份:
    2007
  • 负责人:
    覃瑜君
  • 依托单位: